Abstract:Emerging evidence suggests the critical roles of N6-methyladenosine (m6A) RNA modification in tumorigenesis and tumor progression. However, the role of m6A in non-small cell lung cancer (NSCLC) is still unclear. This study aimed to explore the role of the m6A demethylase fat mass and obesity-associated protein (FTO) in the tumor metastasis of NSCLC. A human m6A epitranscriptomic microarray analysis was used to identify downstream targets of FTO. Quantitative real-time PCR (qRT‒PCR) and western blotting were employed to evaluate the expression levels of FTO and FAP in NSCLC cell lines and tissues. Gain-of-function and loss-of-function assays were conducted in vivo and in vitro to assess the effects of FTO and FAP on NSCLC metastasis. M6A-RNA immunoprecipitation (MeRIP), RNA immunoprecipitation (RIP), luciferase reporter assays, and RNA stability assays were used to explore the mechanism of FTO action. Co-immunoprecipitation (co-IP) assays were used to determine the mechanism of FAP in NSCLC metastasis. FTO was upregulated and predicted poor prognosis in patients with NSCLC. FTO promoted cell migration and invasion in NSCLC, and the FAK inhibitor defactinib (VS6063) suppressed NSCLC metastasis induced by overexpression of FTO. Mechanistically, FTO facilitated NSCLC metastasis by modifying the m6A level of FAP in a YTHDF2-dependent manner. Moreover, FTO-mediated metastasis formation depended on the interactions between FAP and integrin family members, which further activated the FAK signaling. Our current findings provided valuable insights into the role of FTO-mediated m6A demethylation modification in NSCLC metastasis. FTO was identified as a contributor to NSCLC metastasis through the activation of the FAP/integrin/FAK signaling, which may be a potential therapeutic target for NSCLC. Emerging evidence suggests the crucial roles of N6-methyladenosine (m6A) RNA modification in tumorigenesis and progression. Nonetheless, the role of m6A in NSCLC remains unclear. The purpose of this study was to investigate the role of m6A demethylase fat mass and obesity-associated protein (FTO) in the tumor metastasis of non-small cell lung cancer (NSCLC). Results illustrated that FTO was upregulated and predicted poor prognosis in NSCLC patients. FTO promoted cell migration and invasion in NSCLC, and the FAK inhibitor defactinib (VS6063) suppressed NSCLC metastasis induced by overexpression of FTO. Mechanistically, FTO facilitated NSCLC metastasis by modifying the m6A level of FAP in a YTHDF2-dependent manner. Moreover, FTO-mediated metastasis formation depended on the interactions between FAP and integrin family members, which further activated the FAK signaling. Our current findings provided valuable insights into the role of FTO-mediated m6A demethylation modification in NSCLC metastasis. FTO was identified as a contributor to NSCLC metastasis through the activation of the FAP/integrin/FAK signaling, which may be a potential therapeutic target for NSCLC.

LncRNA GAS5 regulated by FTO-mediated m6A demethylation promotes autophagic cell death in NSCLC by targeting UPF1/BRD4 axis

SPI1-induced Downregulation of FTO Promotes GBM Progression by Regulating Pri-Mir-10a Processing in an M6a-Dependent Manner

A Critical Role for the Long Non‐coding RNA GAS5 in Proliferation and Apoptosis in Non‐small‐cell Lung Cancer

Upregulation of Long Noncoding RNA_GAS5 Suppresses Cell Proliferation and Metastasis in Laryngeal Cancer via Regulating PI3K/AKT/mTOR Signaling Pathway

Long Non-Coding RNA-GAS5 Acts As a Tumor Suppressor in Bladder Transitional Cell Carcinoma Via Regulation of Chemokine (C-C Motif) Ligand 1 Expression

Upregulation Of Long Noncoding Rna Gas5 Inhibits Lung Cancer Cell Proliferation And Metastasis Via Mir-205/Pten Axis

Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer

FTO-Mediated Downregulation of RAMP2-AS1 Promotes Glycolysis in Non-Small Cell Lung Cancer Cells by Inhibiting KLF9-Mediated Transcriptional Activation of LATS2

NAT10-mediated upregulation of GAS5 facilitates immune cell infiltration in non-small cell lung cancer via the MYBBP1A-p53/IRF1/type I interferon signaling axis

Downregulation Of Gas5 Promotes Bladder Cancer Cell Proliferation, Partly By Regulating Cdk6

Long Noncoding RNA GAS5 Acts As A Tumor Suppressor in Laryngeal Squamous Cell Carcinoma Via Mir-21.

LncRNA GAS5 Regulates the Wnt/β-catenin Pathway Through the Mir-18A-5p/axin2/gsk3β Axis to Inhibit the Proliferation and Migration of Bladder Cancer Cells.

FTO-mediated autophagy promotes progression of clear cell renal cell carcinoma via regulating SIK2 mRNA stability

FTO Facilitates Cancer Metastasis by Modifying the M 6 A Level of FAP to Induce Integrin/fak Signaling in Non-Small Cell Lung Cancer

LncRNA GAS5 suppresses the tumorigenesis of cervical cancer by downregulating miR-196a and miR-205.

Lncrna GAS5 Enhances G1 Cell Cycle Arrest Via Binding to YBX1 to Regulate P21 Expression in Stomach Cancer.

GAS5 Suppresses Malignancy of Human Glioma Stem Cells via a miR-196a-5p/FOXO1 feedback loop.

Long Noncoding RNA FGD5-AS1 Knockdown Decrease Viability, Migration, and Invasion of Non-Small Cell Lung Cancer (NSCLC) Cells by Regulating the MicroRNA-944/MACC1 Axis

Long Non‑coding RNA GAS5 Increases the Radiosensitivity of A549 Cells Through Interaction with the Mir‑21/pten/akt Axis

Retrospective Study of Gene Signatures and Prognostic Value of M6a Regulatory Factor in Non-Small Cell Lung Cancer Using TCGA Database and the Verification of FTO

Long Non-Coding RNA GAS5 Inhibits Cell Proliferation, Induces G0/G1 Arrest and Apoptosis, and Functions As a Prognostic Marker in Colorectal Cancer.